HC Wainwright Reiterates Buy Rating for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $90.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 29.48% from the company’s previous close.

Other analysts have also recently issued reports about the company. Guggenheim restated a “buy” rating and issued a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. Stifel Nicolaus reduced their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Finally, UBS Group raised their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insmed Price Performance

Shares of NASDAQ INSM opened at $69.51 on Tuesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market capitalization of $12.64 billion, a PE ratio of -12.43 and a beta of 1.07. Insmed has a 1-year low of $21.92 and a 1-year high of $84.91. The business’s fifty day moving average price is $75.14 and its two-hundred day moving average price is $73.59.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. On average, research analysts expect that Insmed will post -4.56 EPS for the current year.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00. Following the completion of the sale, the chief executive officer now owns 379,534 shares of the company’s stock, valued at $29,580,879.96. This trade represents a 4.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 28,390 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,296,751.00. Following the completion of the sale, the chief financial officer now directly owns 155,506 shares of the company’s stock, valued at approximately $12,580,435.40. This represents a 15.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 471,797 shares of company stock worth $37,621,239 over the last 90 days. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. National Bank of Canada FI boosted its stake in shares of Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 147 shares during the period. Abel Hall LLC boosted its position in Insmed by 4.7% during the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 151 shares during the last quarter. Snowden Capital Advisors LLC grew its stake in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC raised its stake in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares in the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 166 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.